|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.04/-1.48
|
企業價值
117.79M
|
資產負債 |
每股賬面淨值
-1.77
|
現金流量 |
現金流量率
--
|
損益表 |
收益
1.38M
|
每股收益
0.02
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 23:59 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |